iNtRON Biotechnology Inc
KOSDAQ:048530
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
i
|
iNtRON Biotechnology Inc
KOSDAQ:048530
|
115.9B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
199B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
192.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
72.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.8B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
iNtRON Biotechnology Inc
Glance View
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for iNtRON Biotechnology Inc is 54.6%, which is below its 3-year median of 59.4%.
Over the last 3 years, iNtRON Biotechnology Inc’s Gross Margin has decreased from 73.8% to 54.6%. During this period, it reached a low of 53.1% on Jun 30, 2025 and a high of 73.8% on Sep 30, 2022.
